4.5 Article

Calcitonin gene-related peptide causes migraine aura

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Clinical Neurology

The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics

William Kristian Karlsson et al.

Summary: The REFORM study aims to discover biomarkers that can predict response to erenumab in migraine patients. This article provides a comprehensive description of the study methodology and the baseline characteristics of the study population. Future publications will report the results of the investigations.

JOURNAL OF HEADACHE AND PAIN (2023)

Review Clinical Neurology

Brain barriers and their potential role in migraine pathophysiology

Astrid Wiggers et al.

Summary: Migraine is a neurological disease involving peptides that can induce vasodilation and affect pain transmission. There is debate whether these peptides act within or outside the central nervous system. Dysfunction of brain barriers during migraine attacks is speculated to facilitate the passage of migraine-inducing peptides into the central nervous system.

JOURNAL OF HEADACHE AND PAIN (2022)

Article Clinical Neurology

Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura A Secondary Analysis of Randomized Clinical Trials

Messoud Ashina et al.

Summary: The study showed that erenumab treatment reduced migraine frequency and AMSM days in patients with migraine with and without aura. The safety and efficacy of using erenumab in this patient population were supported regardless of aura history.

JAMA NEUROLOGY (2022)

Article Clinical Neurology

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2

Messoud Ashina et al.

Summary: This subgroup analysis evaluated the efficacy and safety of eptinezumab for migraine prevention in patients with self-reported aura. The results showed that eptinezumab had comparable preventive efficacy for both episodic and chronic migraine patients with aura, with a similarly favorable safety and tolerability profile as the overall study populations.

CEPHALALGIA (2022)

Article Clinical Neurology

The headache and aura-inducing effects of sildenafil in patients with migraine with aura

Jawad H. Butt et al.

Summary: Sildenafil induces aura and migraine-like headache in patients with migraine with aura, supporting the dissociation between the aura and the headache phase.

CEPHALALGIA (2022)

Review Clinical Neurology

Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD

Andrew M. Strassman et al.

Summary: This study investigated the mechanism of action of Atogepant on activation of mechanosensitive C- and A delta-meningeal nociceptors following cortical spreading depression. The results showed that Atogepant significantly reduced the response amplitude and probability of response in both C- and A delta-fibers at different time intervals.

CEPHALALGIA (2022)

Article Clinical Neurology

Hypersensitivity to calcitonin gene-related peptide in chronic migraine

Afrim Iljazi et al.

Summary: The study revealed that chronic migraine patients are hypersensitive to calcitonin gene-related peptide, with those experiencing ongoing headache being more likely to develop migraine-like attacks after infusion.

CEPHALALGIA (2021)

Article Clinical Neurology

Opening of ATP sensitive potassium channels causes migraine attacks with aura

Mohammad Al-Mahdi Al-Karagholi et al.

Summary: This study found that the ATP-sensitive potassium channel opener levcromakalim may be a novel substance that induces migraine aura in humans. These findings highlight the ATP-sensitive potassium channel as a shared target in migraine aura and migraine headache. Opening of the ATP-sensitive potassium channel likely leads to triggering of aura and headache via distinct mechanisms.
Article Clinical Neurology

Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes

Jean Schoenen et al.

Summary: During a 1-year compassionate use program, 156 patients with migraine self-administered a monthly dose of erenumab 140 mg with a subcutaneous autoinjector. The drug showed significant efficacy in reducing monthly headache days, headache severity, and days with acute drug intake. Adverse effects were generally mild, with constipation being the most frequent. The therapeutic effect was maintained over 12 months, with higher responder rates in patients with episodic migraine compared to chronic migraine.

FRONTIERS IN NEUROLOGY (2021)

Review Medicine, General & Internal

Migraine: disease characterisation, biomarkers, and precision medicine

Messoud Ashina et al.

Summary: The paper discusses the progress made in the search for biomarkers of migraine within genetics, provocation modeling, biochemistry, and neuroimaging research. Challenges and future directions for each biomarker modality are outlined, as well as advances in combining and integrating data from multiple biomarker modalities. These efforts contribute to developing precision medicine for future patients with migraine.

LANCET (2021)

Review Medicine, General & Internal

Migraine: epidemiology and systems of care

Messoud Ashina et al.

Summary: Migraine is a global neurovascular disorder that has negative impacts on patients, families, and society. Integrated and coordinated care systems can help reduce this burden. Low and middle-income countries face challenges in migraine care due to inadequate public health education and access to medication.

LANCET (2021)

Review Clinical Neurology

Updated review on the link between cortical spreading depression and headache disorders

Doga Vuralli et al.

Summary: The traditional understanding of CSD spreading across the hemisphere is invalid in gyrencephalic brains. Thalamocortical dysfunction and interruption of functional cortical network systems by CSD may provide alternative explanations for clinical manifestations of migraine phases including aura.

EXPERT REVIEW OF NEUROTHERAPEUTICS (2021)

Article Clinical Neurology

Hypersensitivity to Calcitonin Gene-Related Peptide in Post-Traumatic Headache

Hakan Ashina et al.

ANNALS OF NEUROLOGY (2020)

Review Medicine, General & Internal

Migraine

Messoud Ashina

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Clinical Neurology

Cortical spreading depression as a site of origin for migraine: Role of CGRP

Liesl N. Close et al.

CEPHALALGIA (2019)

Review Medicine, General & Internal

Targeting calcitonin gene-related peptide: a new era in migraine therapy

Andrew Charles et al.

LANCET (2019)

Article Clinical Neurology

Harold G Wolff

Rebecca Akkermans

LANCET NEUROLOGY (2015)

Review Physiology

SPREADING DEPRESSION, SPREADING DEPOLARIZATIONS, AND THE CEREBRAL VASCULATURE

Cenk Ayata et al.

PHYSIOLOGICAL REVIEWS (2015)

Article Clinical Neurology

Provocation of migraine with aura using natural trigger factors

Anders Hougaard et al.

NEUROLOGY (2013)

Article Clinical Neurology

Migraine headache is present in the aura phase A prospective study

Jakob M. Hansen et al.

NEUROLOGY (2012)

Article Neurosciences

A neural mechanism for exacerbation of headache by light

Rodrigo Noseda et al.

NATURE NEUROSCIENCE (2010)

Article Clinical Neurology

Coexisting typical migraine in familial hemiplegic migraine

Jakob Moller Hansen et al.

NEUROLOGY (2010)

Article Clinical Neurology

Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide

J. M. Hansen et al.

CEPHALALGIA (2008)

Article Pharmacology & Pharmacy

Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat

RJ Storer et al.

BRITISH JOURNAL OF PHARMACOLOGY (2004)

Article Biochemistry & Molecular Biology

Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model

H Bolay et al.

NATURE MEDICINE (2002)

Letter Clinical Neurology

Parallel concept of migraine pathogenesis

ELH Spierings

ANNALS OF NEUROLOGY (2002)

Article Clinical Neurology

Magnetoencephalographic fields from patients with spontaneous and induced migraine aura

SM Bowyer et al.

ANNALS OF NEUROLOGY (2001)